This is a preview of subscription content, log in via an institution to check access.
Notes
Funding for this study was provided by Regeneron Pharmaceuticals, Inc. and Sanofi.
Reference
Konidaris G, et al. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Value in Health : 22 Jan 2021. Available from: URL: https://doi.org/10.1016/j.jval.2020.09.014
Rights and permissions
About this article
Cite this article
Cemiplimab for advanced cutaneous squamous cell carcinoma: survival gains at acceptable cost. PharmacoEcon Outcomes News 871, 7 (2021). https://doi.org/10.1007/s40274-021-7445-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7445-1